FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
FibroBiologics (Nasdaq: FBLG) has filed a patent application for an adhesive bandage using fibroblast cell-based technology for wound healing. This innovative approach aims to leverage the healing properties of fibroblasts in a stable, room-temperature bandage suitable for post-surgical and retail use. The company, which focuses on developing therapeutics for chronic diseases using fibroblasts, sees this as an opportunity to expand its wound care platform and make advanced treatments more accessible.
CEO Pete O'Heeron highlighted the potential for a shelf-stable bandage, while CSO Hamid Khoja, Ph.D., emphasized the transformative potential of fibroblasts in wound care. With over 160 patents issued and pending, FibroBiologics continues to explore novel applications of fibroblast technology in healthcare.
FibroBiologics (Nasdaq: FBLG) ha presentato una domanda di brevetto per un cerotto adesivo basato sulla tecnologia delle cellule fibroblastiche per la guarigione delle ferite. Questo approccio innovativo mira a sfruttare le proprietà curative dei fibroblasti in un cerotto stabile a temperatura ambiente, adatto per l'uso post-operatorio e al dettaglio. L'azienda, che si concentra nello sviluppo di terapie per malattie croniche utilizzando fibroblasti, vede questa come un'opportunità per espandere la sua piattaforma di cura delle ferite e rendere i trattamenti avanzati più accessibili.
Il CEO Pete O'Heeron ha evidenziato il potenziale di un cerotto stabile a lungo termine, mentre il CSO Hamid Khoja, Ph.D., ha sottolineato il potenziale trasformativo dei fibroblasti nella cura delle ferite. Con oltre 160 brevetti emessi e in attesa, FibroBiologics continua a esplorare nuove applicazioni della tecnologia dei fibroblasti nella sanità.
FibroBiologics (Nasdaq: FBLG) ha presentado una solicitud de patente para un vendaje adhesivo utilizando tecnología basada en células fibroblásticas para la curación de heridas. Este enfoque innovador tiene como objetivo aprovechar las propiedades curativas de los fibroblastos en un vendaje estable a temperatura ambiente, adecuado para uso postoperatorio y minorista. La empresa, que se centra en el desarrollo de terapias para enfermedades crónicas utilizando fibroblastos, considera esto como una oportunidad para ampliar su plataforma de cuidado de heridas y hacer que los tratamientos avanzados sean más accesibles.
El CEO Pete O'Heeron destacó el potencial de un vendaje estable en estantería, mientras que el CSO Hamid Khoja, Ph.D., enfatizó el potencial transformador de los fibroblastos en el cuidado de heridas. Con más de 160 patentes emitidas y pendientes, FibroBiologics continúa explorando nuevas aplicaciones de la tecnología de fibroblastos en la atención sanitaria.
FibroBiologics (Nasdaq: FBLG)는 상처 치유를 위한 섬유모세포 기반 기술을 이용한 접착 붕대에 대한 특허 신청서를 제출했습니다. 이 혁신적인 접근 방식은 섬유모세포의 치유 특성을 활용하여 수술 후 및 소매용으로 적합한 실온에서 안정적인 붕대를 개발하는 것을 목표로 하고 있습니다. 만성 질환에 대한 치료제를 개발하는 데 집중하는 이 회사는 이 기회를 통해 상처 치료 플랫폼을 확장하고 고급 치료를 더욱 접근 가능하게 만들 수 있다고 보고 있습니다.
CEO인 Pete O'Heeron은 안정적인 장기간 보관 가능한 붕대의 가능성을 강조했으며, CSO인 Hamid Khoja 박사는 상처 치료에서 섬유모세포의 변혁적인 잠재력에 대해 강조했습니다. 160개 이상의 특허가 발행 및 대기 중인 FibroBiologics는 헬스케어에서 섬유모세포 기술의 새로운 응용을 탐색하는 일을 계속하고 있습니다.
FibroBiologics (Nasdaq: FBLG) a déposé une demande de brevet pour un bandage adhésif utilisant la technologie basée sur les cellules fibroblastiques pour la cicatrisation des plaies. Cette approche innovante vise à exploiter les propriétés de guérison des fibroblastes dans un bandage stable à température ambiante, adapté à un usage post-chirurgical et au détail. La société, qui se concentre sur le développement de thérapies pour les maladies chroniques utilisant des fibroblastes, considère cela comme une opportunité d'élargir sa plateforme de soins des plaies et de rendre les traitements avancés plus accessibles.
Le PDG Pete O'Heeron a souligné le potentiel d'un bandage stable en rayon, tandis que le CSO Hamid Khoja, Ph.D., a mis en avant le potentiel transformateur des fibroblastes dans les soins des plaies. Avec plus de 160 brevets délivrés et en instance, FibroBiologics continue d'explorer de nouvelles applications de la technologie fibroblastique dans le secteur de la santé.
FibroBiologics (Nasdaq: FBLG) hat einen Patentantrag für ein haftendes Pflaster auf Basis von Fibroblastenzelltechnologie zur Wundheilung eingereicht. Dieser innovative Ansatz zielt darauf ab, die heilenden Eigenschaften von Fibroblasten in einem stabilen Pflaster bei Raumtemperatur zu nutzen, das sowohl für den postoperativen als auch den Einzelhandelsgebrauch geeignet ist. Das Unternehmen, das sich auf die Entwicklung von Therapeutika für chronische Erkrankungen mit Fibroblasten konzentriert, sieht hierin eine Gelegenheit, seine Wundpflegerplattform zu erweitern und moderne Behandlungen zugänglicher zu machen.
CEO Pete O'Heeron hob das Potenzial eines lagerstabilen Pflasters hervor, während der CSO Hamid Khoja, Ph.D., das transformative Potenzial von Fibroblasten in der Wundpflege betonte. Mit über 160 erteilten und noch ausstehenden Patenten erforscht FibroBiologics weiterhin neuartige Anwendungen der Fibroblastentechnologie im Gesundheitswesen.
- Filed a patent application for an innovative wound healing adhesive bandage
- Potential to develop a room-temperature, shelf-stable bandage for post-surgical and retail use
- Expansion of the company's wound care platform
- Leveraging unique healing capabilities of fibroblasts for wider accessibility of advanced treatments
- None.
This patent application marks a significant step in wound care innovation. The proposed fibroblast cell-based adhesive bandage could revolutionize post-surgical and retail wound treatment. Fibroblasts play a important role in wound healing by producing extracellular matrix proteins and growth factors. Their incorporation into a room-temperature, shelf-stable bandage could potentially accelerate healing processes and improve outcomes.
However, several challenges lie ahead. The stability of fibroblasts in a bandage format, their viability over time and the regulatory pathway for such a novel product are key hurdles. If successful, this technology could disrupt the
FibroBiologics' patent filing represents a strategic move to expand its intellectual property portfolio and potentially tap into the lucrative wound care market. With 160+ patents already issued or pending, this addition strengthens the company's competitive position. The wound care market, projected to reach
However, investors should note that patent filings don't guarantee market success. The path from patent to product is often long and capital-intensive, especially in biotechnology. FibroBiologics will likely need substantial funding for R&D, clinical trials and regulatory approvals. While the potential is promising, financial risks remain high. Investors should closely monitor the company's cash burn rate, R&D progress and any strategic partnerships that could accelerate commercialization.
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in an adhesive bandage for wound healing.
“Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our wound care platform,” commented Founder & CEO of FibroBiologics, Pete O’Heeron. “This patent, if issued, will allow us to pursue development of a room-temperature, shelf stable bandage that could be used in the post-surgical and retail setting.”
“We believe that leveraging the unique healing capabilities of fibroblasts has the potential to transform wound care as we know it,” added Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D. “Combining the healing properties of fibroblasts with a stable, long-term delivery system could allow us to make advanced treatments more accessible to a wider audience.”
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning potential product candidates, the potential of fibroblasts to transform wound care and FibroBiologics’ ability to make advanced treatments more accessible. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the new patent application filed by FibroBiologics (FBLG) for?
How many patents does FibroBiologics (FBLG) currently have issued and pending?
What are the potential applications of FibroBiologics' (FBLG) new wound healing bandage?
How does FibroBiologics (FBLG) plan to make advanced wound treatments more accessible?
